Development of an intergenotypic Hepatitis C Virus (HCV) cell culture method to assess antiviral susceptibilities and resistance development of HCV NS3 protease genes from HCV genotypes 1 to 6

Journal of Virology

Volumn 84, Issue 9, 2010, Pages 4597-4610

  Imhof, Ingrid ^a   Simmonds, Peter ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CILUPREVIR; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4A;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CELL CULTURE; CHIMERA; CLONE; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG INHIBITION; GENE MUTATION; GENOTYPE; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; JC VIRUS; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; VIRUS GENE; VIRUS REPLICATION;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMALS; ANTIVIRAL AGENTS; CELL CULTURE TECHNIQUES; CELL LINE; DRUG RESISTANCE, VIRAL; GENOTYPE; HEPACIVIRUS; HEPATOCYTES; HUMANS; INHIBITORY CONCENTRATION 50; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; RECOMBINATION, GENETIC; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS, DNA; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

ANIMALIA; HEPATITIS C VIRUS;

EID: 77950848182     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.02698-09     Document Type: Article

References (66)

1. Anonymous. 1999. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J. Viral Hepat. 6:35-47.
2. Bartenschlager, R., V. Lohmann, T. Wilkinson, and J. O. Koch. 1995. Complex formation between the NS3 serine-type proteinase of the hepatitis C virus and NS4A and its importance for polyprotein maturation. J. Virol. 69:7519-7528.
3. Binder, J., S. Tetangco, M. Wick, K. Maegley, L. Lingardo, A. Patick, and G. Smith. 2007. Development of hepatitis C virus (HCV) chimeric replicons for identifying broad spectrum NS3 protease inhibitors. Antiviral Res. 74:A38.
4. Brass, V., J. M. Berke, R. Montserret, H. E. Blum, F. Penin, and D. Moradpour. 2008. Structural determinants for membrane association and dynamic organization of the hepatitis C virus NS3-4A complex. Proc. Natl. Acad. Sci. U. S. A. 105:14545-14550.
5. Bukh, J. 1995. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin. Liver Dis. 15:41-63.
6. Chen, S. L., and T. R. Morgan. 2006. The natural history of hepatitis C virus (HCV) infection. Int. J. Med. Sci. 3:47-52.
7. Choo, Q. L., K. H. Richman, J. H. Han, K. Berger, C. Lee, C. Dong, C. Gallegos, D. Coit, R. Medina Selby, P. J. Barr, A. J. Weiner, D. W. Bradley, G. Kuo, and M. Houghton. 1991. Genetic organization and diversity of the hepatitis C virus. Proc. Natl. Acad. Sci. U. S. A. 88:2451-2455.
8. Cubero, M., J. I. Esteban, T. Otero, S. Sauleda, M. Bes, R. Esteban, J. Guardia, and J. Quer. 2008. Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient. Virology 370:237-245. (Pubitemid 350192568)
9. de Bruijne, J., C. J. Weegink, P. L. Jansen, and H. W. Reesink. 2009. New developments in the antiviral treatment of hepatitis C. Vox Sang. 97:1-12.
10. Failla, C., L. Tomei, and R. Defrancesco. 1994. Both NS3 and NS4A are required for proteolytic processing of hepatitis C virus nonstructural proteins. J. Virol. 68:3753-3760. (Pubitemid 24177400)
11. Failla, C., L. Tomei, and R. Defrancesco. 1995. An amino-terminal domain of the hepatitis C virus NS3 protease is essential for interaction with NS4A. J. Virol. 69:1769-1777.
12. Forestier, N., H. W. Reesink, C. J. Weegink, L. McNair, T. L. Kieffer, H. M. Chu, S. Purdy, P. L. Jansen, and S. Zeuzem. 2007. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology 46:640-648. (Pubitemid 47436108)
13. Franco, S., B. Clotet, and M. A. Martinez. 2008. A wide range of NS3/4A protease catalytic efficiencies in HCV-infected individuals. Virus Res. 131: 260-270. (Pubitemid 351173398)
14. Gottwein, J. M., T. K. H. Scheel, A. M. Hoegh, J. B. Lademann, J. Eugen- Olsen, G. Lisby, and J. Bukh. 2007. Robust hepatitis C genotype 3a cell culture releasing adapted intergenotypic 3a/2a (S52/JFH1) viruses. Gastroenterology 133:1614-1626.
15. Gottwein, J. M., T. K. Scheel, T. B. Jensen, J. B. Lademann, J. C. Prentoe, M. L. Knudsen, A. M. Hoegh, and J. Bukh. 2009. Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. Hepatology 49:364-377.
16. Grakoui, A., C. Wychowski, C. Lin, S. M. Feinstone, and C. M. Rice. 1993. Expression and identification of hepatitis C virus polyprotein cleavage products. J. Virol. 67:1385-1395. (Pubitemid 23067645)
17. Hezode, C., N. Forestier, G. Dusheiko, P. Ferenci, S. Pol, T. Goeser, J. P. Bronowicki, M. Bourliere, S. Gharakhanian, L. Bengtsson, L. McNair, S. George, T. Kieffer, A. Kwong, R. S. Kauffman, J. Alam, J. M. Pawlotsky, and S. Zeuzem. 2009. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N. Engl. J. Med. 360:1839-1850.
18. Hijikata, M., N. Kato, Y. Ootsuyama, M. Nakagawa, and K. Shimotohno. 1991. Gene mapping of the putative structural region of the hepatitis C virus genome by in vitro processing analysis. Proc. Natl. Acad. Sci. U. S. A. 88:5547-5551.
19. Hijikata, M., H. Mizushima, Y. Tanji, Y. Komoda, Y. Hirowatari, T. Akagi, N. Kato, K. Kimura, and K. Shimotohno. 1993. Proteolytic processing and membrane association of putative nonstructural proteins of hepatitis C virus. Proc. Natl. Acad. Sci. U. S. A. 90:10773-10777.
20. Holland-Staley, C. A., L. C. Kovari, E. M. Golenberg, K. J. Pobursky, and D. L. Mayers. 2002. Genetic diversity and response to IFN of the NS3 protease gene from clinical strains of the hepatitis C virus. Arch. Virol. 147:1385-1406.
21. Jensen, T. B., J. M. Gottwein, T. K. Scheel, A. M. Hoegh, J. Eugen-Olsen, and J. Bukh. 2008. Highly efficient JFH1-based cell-culture system for hepatitis C virus genotype 5a: failure of homologous neutralizing-antibody treatment to control infection. J. Infect. Dis. 198:1756-1765.
22. Kuiken, C., K. Yusim, L. Boykin, and R. Richardson. 2005. The Los Alamos hepatitis C sequence database. Bioinformatics 21:379-384. (Pubitemid 40246609)
23. Kuntzen, T., J. Timm, A. Berical, N. Lennon, A. M. Berlin, S. K. Young, B. Lee, D. Heckerman, J. Carlson, L. L. Reyor, M. Kleyman, C. M. McMahon, C. Birch, W. J. Schulze Zur, T. Ledlie, M. Koehrsen, C. Kodira, A. D. Roberts, G. M. Lauer, H. R. Rosen, F. Bihl, A. Cerny, U. Spengler, Z. Liu, A. Y. Kim, Y. Xing, A. Schneidewind, M. A. Madey, J. F. Fleckenstein, V. M. Park, J. E. Galagan, C. Nusbaum, B. D. Walker, G. V. Lake-Bakaar, E. S. Daar, I. M. Jacobson, E. D. Gomperts, B. R. Edlin, S. M. Donfield, R. T. Chung, A. H. Talal, T. Marion, B. W. Birren, M. R. Henn, and T. M. Allen. 2008. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology 48:1769-1778.
24. Lamarre, D., P. C. Anderson, M. Bailey, P. Beaulieu, G. Bolger, P. Bonneau, M. Bos, D. R. Cameron, M. Cartier, M. G. Cordingley, A. M. Faucher, N. Goudreau, S. H. Kawai, G. Kukolj, L. Lagace, S. R. LaPlante, H. Narjes, M. A. Poupart, J. Rancourt, R. E. Sentjens, R. St. George, B. Simoneau, G. Steinmann, D. Thibeault, Y. S. Tsantrizos, S. M. Weldon, C. L. Yong, and M. Llinas-Brunet. 2003. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426:186-189. (Pubitemid 37442587)
25. Lin, C., K. Lin, Y. P. Luong, B. G. Rao, Y. Y. Wei, D. L. Brennan, J. R. Fulghum, H. M. Hsiao, S. Ma, J. P. Maxwell, K. M. Cottrell, R. B. Perni, C. A. Gates, and A. D. Kwong. 2004. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms. J. Biol. Chem. 279:17508-17514.
26. Lindenbach, B. D., M. J. Evans, A. J. Syder, B. Wolk, T. L. Tellinghuisen, C. C. Liu, T. Maruyama, R. O. Hynes, D. R. Burton, J. A. McKeating, and C. M. Rice. 2005. Complete replication of hepatitis C virus in cell culture. Science 309:623-626. (Pubitemid 41033648)
27. Lodrini, S., S. Bagaglio, F. Canducci, M. S. De Mitri, P. Andreone, E. Loggi, A. Lazzarin, M. Clementi, and G. Morsica. 2003. Sequence analysis of NS3 protease gene in clinical strains of hepatitis C virus. J. Biol. Regul. Homeost. Agents 17:198-204.
28. Lu, L., T. J. Pilot-Matias, K. D. Stewart, J. T. Randolph, R. Pithawalla, W. He, P. P. Huang, L. L. Klein, H. Mo, and A. Molla. 2004. Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro. Antimicrob. Agents Chemother. 48:2260-2266.
29. Ludmerer, S. W., D. J. Graham, M. Patel, K. Gilbert, M. Stahlhut, and D. B. Olsen. 2008. A transient cell-based phenotype assay for hepatitis C NS3/4A protease: application to potency determinations of a novel macrocyclic inhibitor against diverse protease sequences isolated from plasma infected with HCV. J. Virol. Methods 151:301-307.
30. Malcolm, B. A., R. Liu, F. Lahser, S. Agrawal, B. Belanger, N. Butkiewicz, R. Chase, F. Gheyas, A. Hart, D. Hesk, P. Ingravallo, C. Jiang, R. Kong, J. Lu, J. Pichardo, A. Prongay, A. Skelton, X. Tong, S. Venkatraman, E. Xia, V. Girijavallabhan, and F. G. Njoroge. 2006. SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. Antimicrob. Agents Chemother. 50:1013-1020.
31. Massariol, M. J., S. Zhao, M. Marquis, D. Thibeault, and P. W. White. 2010. Protease and helicase activities of hepatitis C virus genotype 4, 5, and 6 NS3-NS4A proteins. Biochem. Biophys. Res. Commun. 391:692-697.
32. Mateu, G., R. O. Donis, T. Wakita, J. Bukh, and A. Grakoui. 2008. Intrage-notypic JFH1 based recombinant hepatitis C virus produces high levels of infectious particles but causes increased cell death. Virology 376:397-407.
33. McHutchison, J. G., S. C. Gordon, E. R. Schiff, M. L. Shiffman, W. M. Lee, V. K. Rustgi, Z. D. Goodman, M. H. Ling, S. Cort, and J. K. Albrecht. 1998. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N. Engl. J. Med. 339:1485-1492.
34. Murayama, A., T. Date, K. Morikawa, D. Akazawa, M. Miyamoto, M. Kaga, K. Ishii, T. Suzuki, T. Kato, M. Mizokami, and T. Wakita. 2007. The NS3 helicase and NS5B-to-3′X regions are important for efficient hepatitis C virus strain JFH-1 replication in Huh7 cells. J. Virol. 81:8030-8040. (Pubitemid 47101489)
35. Okamoto, H., M. Kojima, S.-I. Okada, H. Yoshizawa, H. Iizuka, T. Tanaka, E. E. Muchmore, Y. Ito, and S. Mishiro. 1992. Genetic drift of hepatitis C virus during an 8.2 year infection in a chimpanzee: variability and stability. Virology 190:894-899.
36. Pawlotsky, J. M., and J. G. McHutchison. 2004. Hepatitis C. Development of new drugs and clinical trials: promises and pitfalls. Summary of an AASLD hepatitis single topic conference, Chicago, IL, February 27-March 1, 2003. Hepatology 39:554-567.
37. Perni, R. B., S. J. Almquist, R. A. Byrn, G. Chandorkar, P. R. Chaturvedi, L. F. Courtney, C. J. Decker, K. Dinehart, C. A. Gates, S. L. Harbeson, A. Heiser, G. Kalkeri, E. Kolaczkowski, K. Lin, Y. P. Luong, B. G. Rao, W. P. Taylor, J. A. Thomson, R. D. Tung, Y. Wei, A. D. Kwong, and C. Lin. 2006. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob. Agents Chemother. 50:899-909.
38. Pietschmann, T., A. Kaul, G. Koutsoudakis, A. Shavinskaya, S. Kallis, E. Steinmann, K. Abid, F. Negro, M. Dreux, F. L. Cosset, and R. Bartenschlager. 2006. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc. Natl. Acad. Sci. U. S. A. 103:7408-7413.
39. Poynard, T., P. Marcellin, S. S. Lee, C. Niederau, G. S. Minuk, G. Ideo, V. Bain, J. Heathcote, S. Zeuzem, C. Trepo, and J. Albrecht. 1998. Randomised trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 352:1426-1432. (Pubitemid 28510876)
40. Qi, X., A. Bae, S. Liu, H. Yang, S. C. Sun, J. Harris, W. Delaney, M. Miller, and H. Mo. 2009. Development of a replicon-based phenotypic assay for assessing the drug susceptibilities of HCV NS3 protease genes from clinical isolates. Antiviral Res. 81:166-173.
41. Reed, L. J., and H. A. Muench. 1938. Simple method of estimating fifty per cent endpoints. Am. J. Hyg. (Lond.) 27:493-497.
42. Reesink, H. W., S. Zeuzem, C. J. Weegink, N. Forestier, A. van Vliet, J. van de Wetering de Rooij, L. McNair, S. Purdy, R. Kauffman, J. Alam, and P. L. Jansen. 2006. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 131:997-1002.
43. Reiser, M., H. Hinrichsen, Y. Benhamou, H. W. Reesink, H. Wedemeyer, C. Avendano, N. Riba, C. L. Yong, G. Nehmiz, and G. G. Steinmann. 2005. Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology 41:832-835. (Pubitemid 40462946)
44. Sarrazin, C., R. Rouzier, F. Wagner, N. Forestier, D. Larrey, S. K. Gupta, M. Hussain, A. Shah, D. Cutler, J. Zhang, and S. Zeuzem. 2007. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology 132:1270-1278. (Pubitemid 46627577)
45. Scheel, T. K., J. M. Gottwein, T. B. Jensen, J. C. Prentoe, A. M. Hoegh, H. J. Alter, J. Eugen-Olsen, and J. Bukh. 2008. Development of JFH1-based ce culture systems for hepatitis C virus genotype 4a and evidence for crossgenotype neutralization. Proc. Natl. Acad. Sci. U. S. A. 105:997-1002.
46. Seiwert, S. D., S. W. Andrews, Y. Jiang, V. Serebryany, H. Tan, K. Kossen, P. T. Rajagopalan, S. Misialek, S. K. Stevens, A. Stoycheva, J. Hong, S. R. Lim, X. Qin, R. Rieger, K. R. Condroski, H. Zhang, M. G. Do, C. Lemieux, G. P. Hingorani, D. P. Hartley, J. A. Josey, L. Pan, L. Beigelman, and L. M. Blatt. 2008. Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227). Antimicrob. Agents Chemother. 52:4432-4441.
47. Shaw, M. L., J. McLauchlan, P. R. Mills, A. H. Patel, and E. A. McCruden. 2003. Characterisation of the differences between hepatitis C virus genotype 3 and 1 glycoproteins. J. Med. Virol. 70:361-372.
48. Shepard, C. W., L. Finelli, and M. J. Alter. 2005. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis. 5:558-567.
49. Simmonds, P. 1997. Clinical relevance of hepatitis C virus genotypes. Gut 40:291-293. (Pubitemid 27145637)
50. Simmonds, P. 1998. Variability of the hepatitis C virus genome. Curr. Stud. Hematol. Blood Transfus. 62:38-63.
51. Simmonds, P. 2000. Hepatitis C virus genotypes, p. 53-70. In T. J. Liang and J. H. Hoofnagle (ed.), Hepatitis C. Academic Press, San Diego, CA.
52. Simmonds, P., J. Bukh, C. Combet, G. Deleage, N. Enomoto, S. Feinstone, P. Halfon, G. Inchauspe, C. Kuiken, G. Maertens, M. Mizokami, D. G. Murphy, H. Okamoto, J. M. Pawlotsky, F. Penin, E. Sablon, I. Shin, L. J. Stuyver, H. J. Thiel, S. Viazov, A. J. Weiner, and A. Widell. 2005. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42:962-973. (Pubitemid 41401136)
53. Takamizawa, A., C. Mori, I. Fuke, S. Manabe, S. Murakami, J. Fujita, E. Onishi, T. Andoh, I. Yoshida, and H. Okayama. 1991. Structure and organization of the hepatitis C virus genome isolated from human carriers. J. Virol. 65:1105-1113.
54. Tanji, Y., M. Hijikata, S. Satoh, T. Kaneko, and K. Shimotohno. 1995. Hepatitis C virus-encoded nonstructural protein NS4A has versatile functions in viral protein processing. J. Virol. 69:1575-1581.
55. Thibeault, D., C. Bousquet, R. Gingras, L. Lagace, R. Maurice, P. W. White, and D. Lamarre. 2004. Sensitivity of NS3 serine proteases from hepatitis C virus genotypes 2 and 3 to the inhibitor BILN 2061. J. Virol. 78:7352-7359. (Pubitemid 38915881)
56. Ueno, T., S. Inuzuka, M. Sata, H. Koh, S. Tamaki, M. Kin, H. Sugawara, R. Sakata, T. Torimura, and K. Tanikawa. 1995. Serum hyaluronate predicts response to interferon-alpha therapy in patients with chronic hepatitis C. Hepatogastroenterology 42:522-527. (Pubitemid 3007994)
57. Vallet, S., S. Gouriou, J. B. Nousbaum, M. C. Legrand-Quillien, A. Goudeau, and B. Picard. 2005. Genetic heterogeneity of the NS3 protease gene in hepatitis C virus genotype 1 from untreated infected patients. J. Med. Virol. 75:528-537.
58. Vanwolleghem, T., P. Meuleman, L. Libbrecht, T. Roskams, R. De Vos, and G. Leroux-Roels. 2007. Ultra-rapid cardiotoxicity of the hepatitis C virus protease inhibitor BILN 2061 in the urokinase-type plasminogen activator mouse. Gastroenterology 133:1144-1155. (Pubitemid 47494454)
59. Wakita, T., T. Pietschmann, T. Kato, T. Date, M. Miyamoto, Z. J. Zhao, K. Murthy, A. Habermann, H. G. Krausslich, M. Mizokami, R. Bartenschlager, and T. J. Liang. 2005. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11:791-796.
60. Winters, M. A., S. L. Welles, and M. Holodniy. 2006. Hepatitis C virus protease gene diversity in patients coinfected with human immunodeficiency virus. J. Virol. 80:4196-4199.
61. Wright-Minogue, J., N. Yao, R. Zhang, N. J. Butkiewicz, B. M. Baroudy, J. Y. Lau, and Z. Hong. 2000. Cross-genotypic interaction between hepatitis C virus NS3 protease domains and NS4A cofactors. J. Hepatol. 32:497-504. (Pubitemid 30136866)
62. Yanagi, M., R. H. Purcell, S. U. Emerson, and J. Bukh. 1997. Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee. Proc. Natl. Acad. Sci. U. S. A. 94:8738-8743.
63. Yanagi, M., R. H. Purcell, S. U. Emerson, and J. Bukh. 1999. Hepatitis C virus: an infectious molecular clone of a second major genotype (2a) and lack of viability of intertypic 1a and 2a chimeras. Virology 262:250-263. (Pubitemid 29455022)
64. Yi, M., R. A. Villanueva, D. L. Thomas, T. Wakita, and S. M. Lemon. 2006. Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells. Proc. Natl. Acad. Sci. U. S. A. 103:2310-2315.
65. Yi, M. K., Y. H. Ma, J. Yates, and S. M. Lemon. 2007. Compensatory mutations in el, p7, NS2, and NS3 enhance yields of cell culture-infectious intergenotypic chimeric hepatitis C virus. J. Virol. 81:629-638.
66. Zhong, J., P. Gastaminza, J. Chung, Z. Stamataki, M. Isogawa, G. Cheng, J. A. McKeating, and F. V. Chisari. 2006. Persistent hepatitis C virus infection in vitro: coevolution of virus and host. J. Virol. 80:11082-11093. (Pubitemid 44706549)